Skip to Content
Merck
CN

Adenosine receptors as potential targets in melanoma.

Pharmacological research (2013-07-17)
Antonella Montinaro, Raffaella Iannone, Aldo Pinto, Silvana Morello
ABSTRACT

Melanoma is one of the most aggressive types of cancer, that is difficult to manage clinically. A major feature of melanoma cells is their ability to escape immune surveillance. Adenosine receptors play a pivotal role in host immune-surveillance. A2a (A2aR) and, partially, A2bR receptors mediate the adenosine-induced immune-suppression, which markedly facilitates tumor development/progression. On the contrary, A3R stimulation enhances the anti-tumor immune response and thus limits tumor growth. A3R also inhibits the proliferation of many cancer cells. Given that A2aR and A3R have profound effects on tumor growth and metastasis, they are attractive targets for novel therapeutic anti-cancer agents. Here, we review the role played by A2aR and A3R in regulating cancer pathogenesis, with a focus on melanoma, and the therapeutic potential of adenosine receptors pharmacological modulation.

MATERIALS
Product Number
Brand
Product Description

Supelco
Adenosine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Adenosine
Sigma-Aldrich
Adenosine, ≥99%
Sigma-Aldrich
Adenosine, BioReagent, suitable for cell culture
Adenosine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Adenosine, Vetec, reagent grade, 98%